SCHEDULE: T. Rowe Price Boosts Stake in Applied Therapeutics to 14.9%

T. Rowe Price Investment Management, Inc. has disclosed a beneficial ownership of 14.9% in Applied Therapeutics Inc., holding 21,403,300 common shares as of September 30, 2025.

Summary

• T. Rowe Price Investment Management, Inc. reported beneficial ownership of 21,403,300 shares of Applied Therapeutics Inc. common stock.
• This represents 14.9% of the total class of securities.
• The filing is an Amendment No. 3 to a Schedule 13G.
• T. Rowe Price Investment Management, Inc. holds sole voting and sole dispositive power over all 21,403,300 shares.
• T. ROWE PRICE SMALL-CAP VALUE FUND, for which T. Rowe Price Investment Management, Inc. is the investment adviser, holds 12,814,140 shares, representing 8.9% of the class.

Sentiment

Score: 6

Explanation: The filing indicates a significant and potentially increased stake by a major institutional investor, T. Rowe Price, in Applied Therapeutics. While a 13G is a factual disclosure, a large institutional holding can be interpreted as a positive signal of confidence in the company's long-term prospects, hence a slightly positive score.

Positives

• T. Rowe Price Investment Management, Inc. has increased its beneficial ownership in Applied Therapeutics Inc. to 14.9%.
• A significant institutional investor, T. Rowe Price Investment Management, Inc., maintains a substantial stake, indicating continued interest in the company.

Future Outlook

NA

Industry Context

This filing indicates continued or increased confidence from a major institutional investor in Applied Therapeutics, which is common in the investment management industry where large funds take significant positions in public companies.

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability and signal confidence, potentially influencing market perception.
• Company Management: Awareness of a significant institutional holder may influence strategic decisions and communication.

Key Dates

Recommendation

T. Rowe Price Investment Management, Inc.'s disclosure of a 14.9% beneficial ownership in Applied Therapeutics Inc. indicates a substantial and continued institutional interest. While this filing does not provide financial performance data, the significant stake by a reputable investment adviser suggests a level of confidence in the company's long-term prospects. This information alone is insufficient for a definitive buy or sell recommendation, but it warrants a 'hold' for existing investors and signals that the company remains on the radar of major institutional players, prompting further due diligence for new investors.

Keywords

Applied Therapeutics Inc, T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser